Generics

Innovative Products found!

Biosimilars

Medical devices

Nutraceuticals

Filters

Pp-102 manufacturers

Filters

None products found

pp-102

Injection

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
Comments
Indication: Advanced or metastatic non-small cell lung cancer (NSCLC), primarily as part of combination immunotherapy regimens in patients with progressive disease. Clinical stage: Phase 2 global clinical development Modality: mRNA-based cancer immunotherapy (therapeutic vaccine) Mechanism / Target: Encodes multiple tumor-associated antigens to stimulate antigen-specific T-cell responses against lung cancer cells. Route / form: Intravenous administration (lipid nanoparticle–formulated mRNA vaccine) Differentiation: Multi-antigen mRNA vaccine designed to induce broad anti-tumor immune responses and enhance checkpoint inhibitor efficacy in NSCLC.
Manufacturer #38937

Clinical-stage biotechnology company focused on mRNA therapeutics and immunotherapies, primarily in oncology and infectious diseases. Develops precision medicines designed to activate or direct immune responses against disease targets. Strategy emphasizes global clinical development and strategic partnerships.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Interested in Subscription?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.